Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Potent HIV suppression with Darunavir-based antiretroviral therapy (ART) will lead to
repopulation of gastrointestinal-associated lymphoid tissue (GALT) cluster of differentiation
(CD)4+ T-cell populations, normalization of systemic immune activation, and improved
HIV-associated cardiovascular disease (CVD) risk.